Limits...
Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells.

Nyman U, Muppani NR, Zhivotovsky B, Joseph B - J. Cell. Mol. Med. (2011)

Bottom Line: However, the precise mechanism by which TAp73α exerts its pro-survival effect is yet unclear.Finally, we revealed that TAp73β counteracts the anti-apoptotic effect of TAp73α by preventing Hsp72 induction.Our results thus provide additional evidence for the potential oncogenic role of TAp73α, and extend the understanding of the mechanism for its anti-apoptotic effect.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.

Show MeSH

Related in: MedlinePlus

Hsp72 depletion favours Bax activation and loss of ΔΨm upon VP16 treatment in the presence of TAp73α. (A, B) H82 cells were co-transfected with EGFP, asHsp72 vector and empty vector or TAp73α. Cells were treated with VP16 for 24 hrs, stained with TMRE and nuclei counterstained with Hoechst. Loss of ΔΨm was assayed by scoring of EGFP transfected cells without TMRE staining using microscopy (A) and FACS analysis (B). (C) H82 cells were transfected and treated as described (A). Samples were stained with anti-active Bax antibody (red) and nuclei counterstained with Hoechst (blue). (D) Cells were transfected and treated as in (A), stained with anti-active Bax antibody and analysed by FACS.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4373366&req=5

fig04: Hsp72 depletion favours Bax activation and loss of ΔΨm upon VP16 treatment in the presence of TAp73α. (A, B) H82 cells were co-transfected with EGFP, asHsp72 vector and empty vector or TAp73α. Cells were treated with VP16 for 24 hrs, stained with TMRE and nuclei counterstained with Hoechst. Loss of ΔΨm was assayed by scoring of EGFP transfected cells without TMRE staining using microscopy (A) and FACS analysis (B). (C) H82 cells were transfected and treated as described (A). Samples were stained with anti-active Bax antibody (red) and nuclei counterstained with Hoechst (blue). (D) Cells were transfected and treated as in (A), stained with anti-active Bax antibody and analysed by FACS.

Mentions: Significant activation of Bax in H82 cells upon VP16 treatment is observed by FACS analysis at 18–24 hrs after exposure (Fig. S1B). We have previously shown that the anti-apoptotic effect of TAp73α in SCLC cells is exerted upstream of mitochondria, at the level of Bax activation [16]. In addition, Hsp72 has been shown to exert some of its protective effects at the same level, inhibiting apoptosis via the prevention of Bax activation and its translocation to the mitochondria [17]. To investigate whether the simultaneous expression of TAp73α and depletion of Hsp72 could affect the apoptotic process at the level or upstream of mitochondria, H82 cells were co-transfected with TAp73α and asHsp72, and treated with VP16. Indeed, TAp73α was able to prevent VP16-induced disruption of mitochondrial membrane potential (ΔΨm) as shown both by microscopic count of TMRE– cells (Fig. 4A, black bars) and FACS analysis (Fig. 4B, black bars). However, upon co-transfection of TAp73α with asHsp72 the protective effect disappeared leading to a drop in ΔΨm upon VP16 treatment (Fig. 4A and B, TAp73α black and dark grey bars). Moreover, TAp73α-mediated inhibition of Bax activation was eliminated by co-transfection with asHsp72, as depicted by immunofluorescent staining (Fig. 4C) and FACS analysis on percentage of cells staining positive for active Bax (Fig. 4D, black and dark grey bars). Thus, depletion of Hsp72 leads to a loss of TAp73α anti-apoptotic effect upon drug-treatment and favours Bax activation and mitochondrial dysfunctions.


Hsp72 mediates TAp73α anti-apoptotic effects in small cell lung carcinoma cells.

Nyman U, Muppani NR, Zhivotovsky B, Joseph B - J. Cell. Mol. Med. (2011)

Hsp72 depletion favours Bax activation and loss of ΔΨm upon VP16 treatment in the presence of TAp73α. (A, B) H82 cells were co-transfected with EGFP, asHsp72 vector and empty vector or TAp73α. Cells were treated with VP16 for 24 hrs, stained with TMRE and nuclei counterstained with Hoechst. Loss of ΔΨm was assayed by scoring of EGFP transfected cells without TMRE staining using microscopy (A) and FACS analysis (B). (C) H82 cells were transfected and treated as described (A). Samples were stained with anti-active Bax antibody (red) and nuclei counterstained with Hoechst (blue). (D) Cells were transfected and treated as in (A), stained with anti-active Bax antibody and analysed by FACS.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4373366&req=5

fig04: Hsp72 depletion favours Bax activation and loss of ΔΨm upon VP16 treatment in the presence of TAp73α. (A, B) H82 cells were co-transfected with EGFP, asHsp72 vector and empty vector or TAp73α. Cells were treated with VP16 for 24 hrs, stained with TMRE and nuclei counterstained with Hoechst. Loss of ΔΨm was assayed by scoring of EGFP transfected cells without TMRE staining using microscopy (A) and FACS analysis (B). (C) H82 cells were transfected and treated as described (A). Samples were stained with anti-active Bax antibody (red) and nuclei counterstained with Hoechst (blue). (D) Cells were transfected and treated as in (A), stained with anti-active Bax antibody and analysed by FACS.
Mentions: Significant activation of Bax in H82 cells upon VP16 treatment is observed by FACS analysis at 18–24 hrs after exposure (Fig. S1B). We have previously shown that the anti-apoptotic effect of TAp73α in SCLC cells is exerted upstream of mitochondria, at the level of Bax activation [16]. In addition, Hsp72 has been shown to exert some of its protective effects at the same level, inhibiting apoptosis via the prevention of Bax activation and its translocation to the mitochondria [17]. To investigate whether the simultaneous expression of TAp73α and depletion of Hsp72 could affect the apoptotic process at the level or upstream of mitochondria, H82 cells were co-transfected with TAp73α and asHsp72, and treated with VP16. Indeed, TAp73α was able to prevent VP16-induced disruption of mitochondrial membrane potential (ΔΨm) as shown both by microscopic count of TMRE– cells (Fig. 4A, black bars) and FACS analysis (Fig. 4B, black bars). However, upon co-transfection of TAp73α with asHsp72 the protective effect disappeared leading to a drop in ΔΨm upon VP16 treatment (Fig. 4A and B, TAp73α black and dark grey bars). Moreover, TAp73α-mediated inhibition of Bax activation was eliminated by co-transfection with asHsp72, as depicted by immunofluorescent staining (Fig. 4C) and FACS analysis on percentage of cells staining positive for active Bax (Fig. 4D, black and dark grey bars). Thus, depletion of Hsp72 leads to a loss of TAp73α anti-apoptotic effect upon drug-treatment and favours Bax activation and mitochondrial dysfunctions.

Bottom Line: However, the precise mechanism by which TAp73α exerts its pro-survival effect is yet unclear.Finally, we revealed that TAp73β counteracts the anti-apoptotic effect of TAp73α by preventing Hsp72 induction.Our results thus provide additional evidence for the potential oncogenic role of TAp73α, and extend the understanding of the mechanism for its anti-apoptotic effect.

View Article: PubMed Central - PubMed

Affiliation: Department of Oncology-Pathology, Cancer Centrum Karolinska, Karolinska Institutet, Stockholm, Sweden.

Show MeSH
Related in: MedlinePlus